The non-selective Rho-kinase inhibitors Y-27632 and Y-33075 decrease contraction but increase migration in murine and human hepatic stellate cells.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2023
2023
Historique:
received:
22
01
2022
accepted:
07
06
2022
entrez:
31
1
2023
pubmed:
1
2
2023
medline:
3
2
2023
Statut:
epublish
Résumé
The Rho-kinase ROCK II plays a major role in the activation of hepatic stellate cells (HSC), which are the key profibrotic and contractile cells contributing to the development of chronic liver disease. Inhibition of ROCK II ultimately blocks the phosphorylation of the myosin light chain (MLC) and thus inhibits stress fibre assembly and cell contraction. We investigated the effects of the ROCK inhibitors Y-33075 as well as Y-27632 in murine and human hepatic stellate cells. Primary isolated HSC from FVB/NJ mice and the immortalized human HSC line TWNT-4 were culture-activated and incubated with Y-27632 and Y-33075 (10nM to 10μM) for 24h. Protein expression levels were analyzed by Western Blots and transcriptional levels of pro-fibrotic markers and proliferative markers were evaluated using real-time qPCR. Migration was investigated by wound-healing assay. Proliferation was assessed by BrdU assay. Contraction of HSC was measured using 3D collagen matrices after incubation with Y-27632 or Y-33075 in different doses. Both Rho-kinase inhibitors, Y-27632 and Y-33075, reduced contraction, fibrogenesis and proliferation in activated primary mouse HSC (FVB/NJ) and human HSC line (TWNT-4) significantly. Y-33075 demonstrated a 10-times increased potency compared to Y-27632. Surprisingly, both inhibitors mediated a substantial and unexpected increase in migration of HSC in FVB/NJ. ROCK inhibition by the tested compounds decreased contraction but increased migration. Y-33075 proved more potent than Y27632 in the inhibition of contraction of HSCs and should be further evaluated in chronic liver disease.
Sections du résumé
BACKGROUND
The Rho-kinase ROCK II plays a major role in the activation of hepatic stellate cells (HSC), which are the key profibrotic and contractile cells contributing to the development of chronic liver disease. Inhibition of ROCK II ultimately blocks the phosphorylation of the myosin light chain (MLC) and thus inhibits stress fibre assembly and cell contraction. We investigated the effects of the ROCK inhibitors Y-33075 as well as Y-27632 in murine and human hepatic stellate cells.
METHODS
Primary isolated HSC from FVB/NJ mice and the immortalized human HSC line TWNT-4 were culture-activated and incubated with Y-27632 and Y-33075 (10nM to 10μM) for 24h. Protein expression levels were analyzed by Western Blots and transcriptional levels of pro-fibrotic markers and proliferative markers were evaluated using real-time qPCR. Migration was investigated by wound-healing assay. Proliferation was assessed by BrdU assay. Contraction of HSC was measured using 3D collagen matrices after incubation with Y-27632 or Y-33075 in different doses.
RESULTS
Both Rho-kinase inhibitors, Y-27632 and Y-33075, reduced contraction, fibrogenesis and proliferation in activated primary mouse HSC (FVB/NJ) and human HSC line (TWNT-4) significantly. Y-33075 demonstrated a 10-times increased potency compared to Y-27632. Surprisingly, both inhibitors mediated a substantial and unexpected increase in migration of HSC in FVB/NJ.
CONCLUSION
ROCK inhibition by the tested compounds decreased contraction but increased migration. Y-33075 proved more potent than Y27632 in the inhibition of contraction of HSCs and should be further evaluated in chronic liver disease.
Identifiants
pubmed: 36719899
doi: 10.1371/journal.pone.0270288
pii: PONE-D-22-01789
pmc: PMC9888688
doi:
Substances chimiques
rho-Associated Kinases
EC 2.7.11.1
Y 27632
138381-45-0
Y-33075
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0270288Informations de copyright
Copyright: © 2023 Bachtler et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Gastroenterol Hepatol. 2007 Nov;22(11):2022-33
pubmed: 17914985
Mol Vis. 2011;17:1877-90
pubmed: 21850162
Gastroenterology. 2008 May;134(6):1655-69
pubmed: 18471545
Pharm Res. 2011 Aug;28(8):2045-54
pubmed: 21442374
J Hepatol. 2019 Jan;70(1):151-171
pubmed: 30266282
J Hepatol. 2000 May;32(5):762-70
pubmed: 10845663
J Hepatol. 2012 Dec;57(6):1220-7
pubmed: 22878469
Liver Int. 2005 Aug;25(4):829-38
pubmed: 15998434
Small GTPases. 2020 Mar;11(2):131-137
pubmed: 28650698
J Biol Chem. 2001 Jan 5;276(1):341-7
pubmed: 11035001
Am J Physiol Gastrointest Liver Physiol. 2007 Mar;292(3):G806-17
pubmed: 17138966
J Cell Biol. 2005 Aug 1;170(3):443-53
pubmed: 16043513
Neural Regen Res. 2018 Apr;13(4):677-683
pubmed: 29722320
Clin Gastroenterol Hepatol. 2020 Nov;18(12):2650-2666
pubmed: 31401364
Hepatology. 2001 Jan;33(1):74-80
pubmed: 11124823
Mol Neurobiol. 2014 Apr;49(2):900-15
pubmed: 24170433
Curr Opin Struct Biol. 2002 Dec;12(6):761-7
pubmed: 12504681
Hepatology. 1998 Sep;28(3):843-50
pubmed: 9731582
Eur J Pharmacol. 2011 Jan 10;650(1):145-50
pubmed: 20959118
Biochim Biophys Acta. 2015 Oct;1854(10 Pt B):1663-6
pubmed: 25770685
Cells. 2020 Apr 03;9(4):
pubmed: 32260126
Biochemistry. 2012 Sep 25;51(38):7420-32
pubmed: 22931484
Sci Rep. 2019 Feb 19;9(1):2256
pubmed: 30783172
Gut. 2017 Jan;66(1):145-155
pubmed: 26385087
Cancer Sci. 2018 Nov;109(11):3428-3437
pubmed: 30168234
Exp Biol Med (Maywood). 2020 Oct;245(16):1504-1512
pubmed: 32791849
J Cell Mol Med. 2017 Nov;21(11):3100-3112
pubmed: 28661039
Med Oncol. 2011 Jun;28(2):565-71
pubmed: 20300976
Cancer Res. 2009 Nov 15;69(22):8742-51
pubmed: 19887617
Nat Protoc. 2007;2(2):329-33
pubmed: 17406593
J Cell Sci. 2007 Oct 15;120(Pt 20):3491-9
pubmed: 17928305
Gut. 2006 Sep;55(9):1296-305
pubmed: 16492715
Methods Mol Med. 2005;117:99-113
pubmed: 16118448
Cold Spring Harb Protoc. 2010 Jun;2010(6):pdb.prot5439
pubmed: 20516177
Liver Int. 2020 Sep;40(9):2228-2241
pubmed: 32627946
J Clin Invest. 2005 Feb;115(2):209-18
pubmed: 15690074
Int J Gynecol Cancer. 2009 Dec;19(9):1473-80
pubmed: 19955921
PLoS One. 2014 Feb 11;9(2):e88489
pubmed: 24523903
Transl Vis Sci Technol. 2016 Nov 22;5(6):7
pubmed: 27917311
Front Biosci. 2002 Aug 01;7:d1720-6
pubmed: 12133817
Semin Liver Dis. 2001 Aug;21(3):385-95
pubmed: 11586467
Int J Cell Biol. 2012;2012:259142
pubmed: 22690219
J Pharmacol Exp Ther. 2011 Jun;337(3):628-35
pubmed: 21383021
Biochem J. 2007 Jan 15;401(2):377-90
pubmed: 17173542
JHEP Rep. 2021 Oct 06;4(1):100386
pubmed: 34917911